A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (FPEB)
Measurement of metabotropic glutamate receptor type 5 (mGluR5) binding capacity in the brain, may be a valuable tool in the early detection, understanding, or evaluation of Parkinson disease (PD), Huntington disease (HD), Fragile X syndrome (FXS), Autism Spectrum Disorder(ASD), Alzheimer's Disease(AD), and subjects with mild cognitive impairment (MCI).
The goal of this study is to assess [18F]F-PEB positron emission tomography (PET) imaging as a tool to detect mGluR5 density in the brain of PD, HD, FXS ASD, AD, and MCI research participants and similarly aged healthy subjects.
Autistic Spectrum Disorders
Fragile X Syndrome
Mild Cognitive Impairment
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions|
- Does FPEB reliably represent the known distribution of MGLUR5 in the brain? [ Time Frame: at completion of scans ] [ Designated as safety issue: Yes ]
|Study Start Date:||March 2009|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Assess [18F]FPEB and PET imaging
To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
Other Name: Fluorine-18
Informed consent will be obtained for all subjects. All subjects will undergo a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. All subjects will undergo [18F]F-PEB PET imaging. Subjects may also be asked to undergo standard brain MRI to assist in the analysis of the PET images obtained.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00870974
|Contact: Debbie Stottleemail@example.com|
|United States, Connecticut|
|Institute for Neurodegenerative Disorders||Recruiting|
|New Haven, Connecticut, United States, 06510|
|Contact: Debbie Stottle 203-401-4300 firstname.lastname@example.org|
|Principal Investigator: David Russell, MD,PhD|
|Sub-Investigator: Danna Jennings, MD|
|Principal Investigator:||David Russell, MD||Institute for Neurodegenerative Disorders|